Prelude Therapeutics

Prelude Therapeutics

Biotechnology, 200 Powder ML Rd, Wilmington, Delaware, 19803, United States, 51-200 Employees

preludetx.com

  • twitter
  • LinkedIn

Who is PRELUDE THERAPEUTICS

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Companys diverse pipeline is compris...

Read More

map
  • 200 Powder ML Rd, Wilmington, Delaware, 19803, United States Headquarters: 200 Powder ML Rd, Wilmington, Delaware, 19803, United States
  • 2016 Date Founded: 2016
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies
  • Kris Vaddi CEO:   Kris Vaddi

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from PRELUDE THERAPEUTICS

Prelude Therapeutics Org Chart and Mapping

Kris Vaddi

Chief Executive Officer and Founder

VP-Level
VP-Level
Employees

Sarah Rowe

Associate Director, Clinical Operations

David Dodsworth

Sr. Director Quality Assurance

Ganfeng 曹敢峰

Vice President and Head of Process Chemistry, Cmc

Jeffrey Edonick

Information Technology Operations Manager

Karl Blom

Executive Director, Discovery Chemistry Analytical

Diane Heiser

Vice President, Translationl Research and Hematology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Prelude Therapeutics

Answer: Prelude Therapeutics's headquarters are located at 200 Powder ML Rd, Wilmington, Delaware, 19803, United States

Answer: Prelude Therapeutics's official website is https://preludetx.com

Answer: Prelude Therapeutics's revenue is $25 Million to $50 Million

Answer: Prelude Therapeutics's SIC: 2834

Answer: Prelude Therapeutics has 51-200 employees

Answer: Prelude Therapeutics is in Biotechnology

Answer: Prelude Therapeutics contact info: Phone number: Website: https://preludetx.com

Answer: Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Companys diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Preludes pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access